Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.

Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH.

Clin Microbiol Infect. 2014 Feb;20(2):O90-O100. doi: 10.1111/1469-0691.12220.

2.

A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.

Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.

J Antimicrob Chemother. 2012 Mar;67(3):696-9. doi: 10.1093/jac/dkr495.

4.

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.

Zhang Y, Hu P, Qi X, Ren H, Mao RC, Zhang JM.

Clin Microbiol Infect. 2016 Mar;22(3):287.e1-9. doi: 10.1016/j.cmi.2015.10.024.

PMID:
26548508
5.
6.

Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.

Law ST, Lee MK, Li KK, Mok CK.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):193-8. doi: 10.1097/MEG.0000000000000519.

PMID:
26587867
7.

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Am J Gastroenterol. 2011 Jul;106(7):1264-71. doi: 10.1038/ajg.2011.45.

PMID:
21364549
8.

Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.

Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH, Hu TH.

J Gastroenterol Hepatol. 2014 Mar;29(3):568-75.

PMID:
24716215
9.

The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.

Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J.

Hepatology. 2014 Apr;59(4):1283-92. doi: 10.1002/hep.26885.

PMID:
24382690
10.

Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.

Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL.

Antivir Ther. 2013;18(5):671-9. doi: 10.3851/IMP2526.

PMID:
23462214
11.

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.

Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C.

Liver Int. 2011 May;31(5):676-84. doi: 10.1111/j.1478-3231.2011.02490.x.

PMID:
21457439
12.

Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.

Su QM, Ye XG.

World J Gastroenterol. 2012 Nov 21;18(43):6290-301. doi: 10.3748/wjg.v18.i43.6290. Review.

13.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037.

PMID:
22659518
14.

Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients.

Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW.

J Viral Hepat. 2010 Mar;17 Suppl 1:51-8.

PMID:
20586934
15.

[Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].

Huang J, Chen XP, Chen XF, Chen WL, Chen R, Ma XJ, Luo XD.

Zhonghua Gan Zang Bing Za Zhi. 2011 Mar;19(3):178-81. doi: 10.3760/cma.j.issn.1007-3418.2011.03.007. Chinese.

PMID:
21586234
16.

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV.

J Viral Hepat. 2013 Apr;20(4):e37-46. doi: 10.1111/jvh.12025.

17.

Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.

Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.

Liver Int. 2015 Mar;35(3):860-9. doi: 10.1111/liv.12605.

PMID:
24905912
18.

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.

Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y.

Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472.

19.

Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.

Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P, Lee HC, Avila C, Zeuzem S.

Antimicrob Agents Chemother. 2010 Mar;54(3):1242-7. doi: 10.1128/AAC.01163-09.

20.

Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.

Lü W, Yang HH, Fan YM, Li T, Zhang LF, Mui C, Fan HW, Zhou BT, Liu ZY, Ng H, Liu XQ.

Chin Med J (Engl). 2013 Jun;126(12):2333-6.

Items per page

Supplemental Content

Support Center